H 1337

Drug Profile

H 1337

Alternative Names: ALY-1337; H-1337

Latest Information Update: 09 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator D. Western Therapeutics Institute
  • Developer Allysta Pharmaceuticals; D. Western Therapeutics Institute
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glaucoma

Most Recent Events

  • 16 Mar 2018 Phase-I/II clinical trials in Glaucoma (In adults, In the elderly) in USA (unspecified route) (NCT03452033)
  • 02 Mar 2018 Allysta Pharmaceutical plans a phase I/IIa trial for Glaucoma in USA (Ophthalmic) (NCT03452033)
  • 14 Apr 2016 D. Western Therapeutics Institute and Allysta Pharmaceuticals enter into a strategic collaboration for the development of H 1337
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top